Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
EBITDA Growth
-149.17%
TTM · Period ending:
LCTX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-149.17%period ending
Latest reported-149.17%period ending
LCTX TTM EBITDA YoY % (-20.00% → -149.17%)
Year-over-year change
High-resolution chart · PNG
LCTX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 34.06% | |
| 27.5598% | |
| 13.1605% | |
| 1.0835% | |
| -73.0018% | |
| -62.0801% | |
| -37.5% | |
| 2.5641% | |
| 11.3636% | |
| -14.2857% | |
| -30% | |
| -12.8205% | |
| -12.1212% | |
| -40% | |
| -30.4348% | |
| -290% | |
| -106.25% | |
| -8.6957% | |
| 0% | |
| 52.381% | |
| 11.1111% | |
| -53.3333% | |
| -64.2857% | |
| -75% | |
| -50% | |
| -25% | |
| -27.2727% | |
| -9.0909% | |
| -20% |